SMART Clinical Study: Surgical Multi-center Assessment of RF Ablation for the Treatment of Vertebrogenic Back Pain

This study is currently recruiting participants.
Verified September 2012 by Relievant Medsystems, Inc.
Sponsor:
Information provided by (Responsible Party):
Relievant Medsystems, Inc.
ClinicalTrials.gov Identifier:
NCT01446419
First received: October 3, 2011
Last updated: September 11, 2012
Last verified: September 2012
  Purpose

To evaluate the safety and efficacy of RF ablation using the Intracept Intraosseous Nerve Ablation System to ablate intraosseous nerves for the relief of chronic axial low back pain. This is a prospective, double-blind, randomized, sham-controlled clinical trial with an optional crossover component.


Condition Intervention
Low Back Pain
Device: Intracept Treatment

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain

Resource links provided by NLM:


Further study details as provided by Relievant Medsystems, Inc.:

Primary Outcome Measures:
  • Oswestry Disability Index [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    The primary variable is the Oswestry Disability Index (ODI) and the primary efficacy endpoint is the mean improvement from baseline to 3 months in the ODI. The primary endpoint will be evaluated in both the treatment and sham groups with between-group comparisons used to assess the success of the Intracept System in reducing chronic axial low back pain.


Secondary Outcome Measures:
  • Patient Success at 3 months and Oswestry Disability Index at 6 months [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 200
Study Start Date: October 2011
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Intracept Treatment Device: Intracept Treatment
Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
Sham Comparator: Sham Treatment Device: Intracept Treatment
Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.

  Eligibility

Ages Eligible for Study:   25 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Skeletally mature patients age 25 - 70 years, inclusive
  • Chronic lower back pain for at least six (6) months
  • Failure to respond to at least six (6) months of non-operative conservative management. The minimum requirment is as follows:

    • Analgesic therapy (minimum of 2 weeks) and a minimum of 4 weeks of NSAID therapy
    • Supervised exercise program(minimum of 12 sessions)
  • Oswestry Disability Index (ODI) at time of evaluation of at least 30 points
  • Baseline Visual Analog Scale (VAS) of at least 4cm on a 10cm scale
  • The following test indicating that the vertebral body is the source of pain:

    1.MRI showing Type 1 or Type II Modic changes at least one vertebral endplate, at one or more levels from L3 to S1

  • Understands the local language and is willing and able to follow the requirements of the protocol
  • Understands the informed consent and signs the institutional review board/ independent ethics committee (IRB/IEC) approved informed consent form

Exclusion Criteria:

  • Radicular pain by history or evidence of pain or neurological deficit in a dermatonal zone at or below the medial thigh.
  • Previous surgery performed on the lumbar spine
  • History of symptomatic spinal stenosis
  • History of osteoporotic or tumor-related vertebral body compression fracture
  • History of vertebral cancer or spinal metastasis
  • History of spinal infection
  • Metabolic bone disease (e.g. osteogenesis imperfecta)
  • BMI ≥40
  • Osteoporosis, defined as T score <-2.5
  • Any radiographic evidence of other important back pathology, such as:

    1. Nerve root compression or severe effacement of the thecal sac that correlates with radicular pain or muscle weakness
    2. Disc extrusion or disc protrusion >5mm
    3. Facet arthrosis or facet effusion at any lumbar level that correlates with clinical evidence of facet mediated low back pain
    4. Spondylolisthesis 2mm or greater at any level
    5. Spondylolysis at any level
  • MRI evidence of Modic changes, Type I or Type II at greater than 3 vertebral bodies.
  • Any back pathology related to trauma, evidence of vertebral compression fracture or other spinal pathology that could affect assessment of response to back pain
  • Demonstrates 3 or more Waddell's signs of Inorganic Behavior
  • Any evidence of current systemic infection
  • Uncorrected bleeding diathesis
  • Any neurologic problem that prevents early mobilization after surgery or interferes with assessment of ODI
  • Contraindication to MRI or patients who have allergies to the components of the Intracept device
  • Pregnant, lactating or plan to become pregnant in next year
  • Diabetes requiring daily insulin
  • Current use of steroid therapy, with the exception of inhalation steroids for asthma
  • Evidence of mental instability or uncontrolled depression; patients requiring anti-depressants or anti-psychotics within 3 months of enrollment are not eligible; patients with a Beck Depression Score of greater than 24 are not eligible
  • Receiving Workmen's Compensation
  • Currently involved in litigation regarding back pain/injury or financial incentive to remain impaired
  • Any medical condition that impairs follow-up
  • Contraindications to the proposed anesthetic protocol.
  • Evidence of substance abuse; patients using prescribed extended release narcotics are not eligible (e.g. fentanyl patch,MS contin, oxycontin)
  • Known to require at the time of screening and/or randomization, additional surgery to the lumbar spinal region within six months
  • Being treated with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone use up to 5 mg/qd or its equivalent is allowed)
  • Has a life expectancy of less than 1 year
  • Has active implantable devices, such as cardiac pacemakers, spinal cord stimulators, etc.
  • Is a prisoner
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01446419

Locations
United States, Arizona
Desert Institute for Spine Care Recruiting
Phoenix, Arizona, United States, 85020
Contact: Jennifer Camoriano     480-695-0681     jennifer@jehnresearch.com    
Principal Investigator: Christopher Yeung, MD            
Sub-Investigator: Anthony Yeung, MD            
Sub-Investigator: Justin Field, MD            
United States, California
Memorial Orthopedic Surgical Group Recruiting
Long Beach, California, United States, 90806
Contact: Nanette Chavez     888-978-8396     nanettechavez@gmail.com    
Principal Investigator: Phil Yuan, MD            
Sub-Investigator: Curtis Spencer, MD            
Sub-Investigator: Kasra Rowshan, MD            
The Spine Institute Recruiting
Santa Monica, California, United States, 90403
Contact: Annie Sharabidze     888-978-8396     Annie.Sharabidze@cshs.org    
Principal Investigator: Hyun Bae, MD            
Sub-Investigator: Timothy Davis, MD            
United States, Georgia
Pain Center Solutions Recruiting
Marietta, Georgia, United States, 30060
Contact: Austin Filitor     888-978-8396     afilitor@drugstudies.net    
Principal Investigator: Michael Schaufele, MD            
Sub-Investigator: Marvin Tark, MD            
United States, Indiana
Indiana Spine Group Recruiting
Carmel, Indiana, United States, 46032
Contact: Sheetal Vinayek     317-715-5897     svinayek@indianaspinegroup.com    
Principal Investigator: Rick Sasso, MD            
Sub-Investigator: Kevin Macadaeg, MD            
United States, Maine
Maine Medical Partners Recruiting
Scarborough, Maine, United States, 04074
Contact: Deborah Cushing     888-978-8396     cushid@mmc.org    
Principal Investigator: Lee Thibodeau, MD            
Sub-Investigator: Douglas Buxton, MD            
United States, Michigan
Partners in Research and Educational Studies of Spinal Disorders (PressD) Recruiting
Southfield, Michigan, United States, 48033
Contact: Claudia Westbrook, RN     888-978-8396     smartstudycjw@gmail.com    
Principal Investigator: Lawrence T Kurz, MD            
Sub-Investigator: Michael Sikorsky, MD            
Sub-Investigator: Dan Park, MD            
United States, North Carolina
OrthoCarolina Recruiting
Charlotte, North Carolina, United States, 28207
Contact: Caryn Thompson     704-323-2778     caryn.thompson@orthocarolina.com    
Contact: Rebekah Smith     704-323-2278     rebekah.smith@orthocarolina.com    
Principal Investigator: Alfred Rhyne, MD            
Sub-Investigator: Sarjoo Bhagia, MD            
United States, Oregon
NeuroSpine Institute Recruiting
Eugene, Oregon, United States, 97401
Contact: Shawn Potts     541-393-0100     spotts@neurospinellc.com    
Principal Investigator: Scott Kitchel, MD            
Sub-Investigator: Greg Moore, MD            
United States, Pennsylvania
Rothman Institute Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: AnneMarie Madden     888-978-8396     annemarie.madden@rothmaninstitute.com    
Contact: Victor Popov     888-978-8396     victor.popov@rothmaninstitute.com    
Principal Investigator: D. Greg Anderson, MD            
Sub-Investigator: Kristen Radcliff, MD            
Sponsors and Collaborators
Relievant Medsystems, Inc.
Investigators
Principal Investigator: Jeffrey Fischgrund, MD Michigan Orthopaedic Institute
  More Information

No publications provided

Responsible Party: Relievant Medsystems, Inc.
ClinicalTrials.gov Identifier: NCT01446419     History of Changes
Other Study ID Numbers: CIP 0003
Study First Received: October 3, 2011
Last Updated: September 11, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Relievant Medsystems, Inc.:
chronic axial low back pain
vertebrogenic pain
Radio frequency ablation

Additional relevant MeSH terms:
Back Pain
Low Back Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on May 19, 2013